SLC6A3 and Parkinson disease: While reporting that APOE ε2/ε4 may be involved in accelerating brain atrophy or reduction of dopaminergic neurons (as quantified by DAT striatal binding ratio (SBr)) in PD, we also report that subjects with PD exhibit intrinsic heterogeneity, which may stem from genetic factors.